Global investment firm Carlyle has announced a strategic investment of €250 million in Sanoptis, a European leader in ophthalmology services. The funding, provided through Carlyle’s Global Credit platform, is intended to support Sanoptis’ growth and expansion across Europe. The company plans to use the capital for mergers and acquisitions as well as investing in advanced technologies and treatments.
Sanoptis, majority-owned by Groupe Bruxelles Lambert (GBL), operates over 450 locations in Germany, Switzerland, Italy, Spain, Austria, and Greece. With approximately 4,700 employees, the company conducts around 3.3 million treatments annually.
Adnan Khalef from Carlyle’s European Private Credit business expressed enthusiasm about the partnership: “We are delighted to provide this strategic investment to Sanoptis in order to strengthen and expand their leading position in ophthalmology services in Europe.” He also noted the collaboration with GBL as beneficial due to their focus on long-term value creation.
Volker Wendel, CEO and Founder of Sanoptis, commented on the new partnership: “We are very excited that Carlyle is joining us as a new partner alongside our lead investor GBL.”
Michal Chalaczkiewicz from GBL shared his excitement about working with Carlyle: “Carlyle’s track record and confidence in this endeavour further attests to the value-creation potential this platform holds.”
Carlyle’s Global Credit platform manages $192 billion in assets as of December 31, 2024. This transaction follows the final close of Carlyle Credit Opportunities Fund III which raised $7.1 billion.
Jefferies served as the sole financial adviser for Sanoptis and GBL during this transaction.
